PCM
ADMS

Prelude Capital Management’s Adamas Pharmaceuticals ADMS Stock Holding History

Prelude Capital Management’s Portfolio ADMS Stock Details ADMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-3,402
Closed -$9K – 2553
2020
Q2 		$9K Buy
+3,402
New +$10K ﹤0.01% 1609
2018
Q1 		– Sell
-14,051
Closed -$476K – 1802
2017
Q4 		$476K Buy
+14,051
New +$392K 0.04% 439
2016
Q2 		– Sell
-1,667
Closed -$24K – 1808
2016
Q1 		$24K Buy
+1,667
New +$28.1K ﹤0.01% 1087

Other funds holding ADMS

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DAM
Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return

Prelude Capital Management's ADMS Position: Q3 2020 in Review

Prelude Capital Management sold out of Adamas Pharmaceuticals (ADMS) in Q3 2020, closing a stake of 3,402 shares — an estimated $9K sold.

Prelude Capital Management first reported a position in ADMS in Q1 2016 and held it in 3 quarters. The position peaked at $476K in Q4 2017. 63 funds tracked by Wall St. Rank hold ADMS as of Q3 2020.

  • Prelude Capital Management reported no remaining Adamas Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
  • Prelude Capital Management sold 3,402 Adamas Pharmaceuticals shares in Q3 2020, an estimated $9K.
  • Prelude Capital Management first reported a position in Adamas Pharmaceuticals in Q1 2016 and held it in 3 quarters.
  • Prelude Capital Management's Adamas Pharmaceuticals position peaked at $476K in Q4 2017.
  • 63 funds tracked by Wall St. Rank held Adamas Pharmaceuticals as of Q3 2020.

Based on Prelude Capital Management's 13F filing for Q3 2020, filed 16 Nov 2020.